IOSR Journal Of Pharmacy And Biological Sciences (IOSR-JPBS)
e-ISSN:2278-3008, p-ISSN:2319-7676. Volume 16, Issue 2 Ser. II (Mar. – Apr. 2021), PP 01-08
www.Iosrjournals.Org

Preparation and Development of Tamarind Seed Polysaccharide-Coated Nanostructured Lipid Carriers for Oral Delivery of Nifedipine

Birendra Shrivastava[1], Kush Anuradha[2] , Rashmi Manchanda[3]

1. *Department of Pharmaceutical Chemistry, Jaipur National University, Jaipur-302001, Rajasthan, India*
2. *Department of Pharmaceutics Sciences, R.K.S.D. College of Pharmacy, Kaithal-136027, Haryana, India (Corresponding Author)*
3. *Anuradha Kush, Department of Pharmaceutics Sciences, R.K.S.D. College of Pharmacy, Kaithal-136027, Haryana, India*

Abstract
The present study is aimed at preparation and development of Nanostructured lipid carriers from natural polysaccharide extracted from Tamarind seeds (Tamarindus indica) for the sustained delivery of Nifedipine. The Nifedipine loaded NLCs were prepared by solvent injection technique with the isolated tamarind seed polysaccharide. The formulations were optimized using two level factorial design using the polysaccharide, solid lipid and liquid lipid as independent variables and particle size (PS), drug entrapment efficiency as the dependent variables. The NLCs were characterized in terms of PS, entrapment efficiency, in vitro drug release and Scanning Electron Microscopy. Stable NLCs were obtained with average PS of 285.1 ± 4.6 nm. The entrapment efficiency of optimized batch was found to be 82.56 ± 2.5% (w/w). In vitro drug release showed controlled release pattern showing up to 90% release in 24 h. It may be concluded from the study that tamarind seed polysaccharides may be suitable for formulation of NLCs for better efficacy and sustained delivery of hypertensive drug Nifedipine.

Keywords: *Nifedipine, NLCs, Characterization, In Vitro Drug Release, Tamarind seed polysaccharide*

Date of Submission: 20-03-2021 Date of Acceptance: 04-04-2021

I. Introduction

Lipid-based drug delivery systems are predicted as promising oral carriers due to their prospective to enhance the solubility and increased oral bioavailability of drugs having low water-solubility and/or lipophilicity **(1).** Standard lipid-based formulations have a broad range of lipid solution, emulsions, liposomes, lipid microparticles and nanoparticles. In between the formulations above, the nanostructure lipid carriers (NLCs) are considered as the second-generation of lipid nanoparticles **[2],** and are attracting vital attention as substitute of colloidal drug carriers. Mucoadhesive NLCs coated with hydrophilic polysaccharides may also sustain the release of drug and hence also can improve bioavailability.

Nifedipine, a poorly soluble drug with calcium channel blocker activity utilized in hypertension treatment. It is the most vascular selective dihydropyridine with antioxidant effect. Nifedipine exhibits a high first-pass hepatic metabolism with 45% bioavailability. The complete metabolism of Nifedipine occurs in the liver by cytochrome P450 3A4 to pharmacologically inactive metabolites. Nifedipine has small water solubility and could be classified as a BCS class II drug **[3].** Tamarind tree belongs to dicotyledonous family *Leguminosae*. Tamarind seed polysaccharide (TSP) is extracted from the seed kernel of *Tamarindus indica* which possesses high viscosity, broad pH tolerance, non-carcinogenicity, mucoadhesive property and biocompatibility.[4,5] Tamarind seed polysaccharide (TSP) shows sustained release behavior for both hydrophilic and lipophillic drugs **[6].** TSP has also shown high drug loading capacity **[7]** and high thermal stability **[8**]. TSP has been used as excipient in hydrophilic drug delivery system. Different mucoadhesive preparations have been formulated using TSP for drugs such as Gentamycin, Ofloxacin, **[9]** Paclitaxel,[**10]** Ketotifen Fumarate with enhanced efficacy.

II. Materials and Methods

2.1 Materials and Methods

The tamarind seeds were collected locally. All the chemicals used during the project are of analytical grade. Irinotecan hydrochloric acid (HCl) was purchased from Nice Laboratory Reagents, Kochi, India. Ethanol

was purchased from Merck Ltd., India. Nifedipine, Glycerol monostearate (GMS), oleic acid (O.A), isopropyl alcohol were purchased from Balaji chemicals, Surat, India. Poloxamer 188 was purchased from Crystal Chemicals, Gangtok, India.

2.1 Isolation of TSP

To isolate TSP 20 g of tamarind kernel powder was taken, 200 ml of cold distilled water was utilized to make slurry. The slurry was then poured into 800 ml boiling distilled water. The solution was boiled for 20 minutes with continuous stirring. The resulting clear solution was kept overnight so that most of the fibers settle down. The solution was then centrifuged at 5000 rpm for 20 min. The supernatant solution was separated out and poured into twice the volume of absolute Ethanol by continuous stirring to obtain the precipitate. The precipitate was washed twice with absolute ethanol and dried at room temperature for 2 days. The dried product was grounded and passed through BSS # 60 and stored in dessicator till further use **[11].**

2.2 Preparation of Nifedipine loaded NLCs with TSP

Nanostructured lipid carriers were prepared by solvent injection technique with slight modification **[12].** Nifedipine and specified amount of Glycerol monostearate (GMS) and oleic acid were dissolved in 4 ml of isopropyl alcohol (boiling point 81–83°C) with heating at the melting temperature of GMS. The resulting solution was rapidly injected into the 100 mL aqueous phase containing polysaccharide at 0.4 mg/mL **[13]** and poloxamer at 0.4 mg/mL with continuously stirring at 400 rpm for 30 min on a magnetic stirrer and then 0.1 N HCl (8 ml) was added to the dispersion.

Thereafter, the dispersion was centrifuged at 10,000 rpm for 30 min at 10°C in REMI cooling centrifuge (Model C- 24BL, VACO-779, Vasai, India), and aggregates were re-suspended in 10 ml double distilled water containing 4% poloxamer 188 (by weight) as stabilizer with stirring at 1000 rpm for 10 min**. [14].** Purification of Nifedipine loaded NLCs was done by dialysis technique. Re-suspended suspension was taken in the dialysis bag and sealed at both ends. The dialysis bag then immersed into 100 ml of double distilled water containing 0.2% (w/v) sodium lauryl sulphate and stirred at 100 rpm for 20 min. The unentrapped drug has been removed in the 20 min. The HPLC was performed by using HPLC (Jasco) C18 column. A mixture of methanol: water (85:15 v/v) was used as mobile phase. The flow rate of mobile phase, injection volume and detection wavelength were 1.0 ml/min, 20µl and 350nm respectively. Nifedipine showed linear calibration curve with R^2 =0.997 in the range 50-250µg/ml.

Table 1: Formulation Design of NLCs.

Formulation Code	GMS(mg)	O.A(mg)	TSP(mg)
T_1	100	10	40
T_2	200	10	40
T_3	100	20	40
T_4	200	20	40
T_5	100	10	50
T_6	200	10	50
T_7	100	20	50
T_8	200	10	50

2.3 Characterization of NLC

2.3.1 Particle size

The all preparations of NLCs were characterized for their size by utilizing digital microscope (BA-310, Motic, USA). NLCs were dispersed in 10ml of water. From the dispersion, a drop of sample was put down on glass slide and covered with cover slip. The slide then analysed under digital microscope under 40X magnification. The size of NLCs was also studied by Zetasizer at 25°C at an angle of 90°, taking the average of three measurements.

2.3.2 Drug Entrapment Efficiency (DEE %)

The drug entrapment was measured by RP-HPLC method using methanol: water (85:15 v/v) as a mobile phase. 1ml of Nifedipine loaded NLCs colloidal solution centrifuged for 10 min at 4000rpm. Then the solution was filtered through a 0.45µm membrane filter. After that, it analysed by HPLC **[15].** Drug entrapment efficiency (DEE) of nanostructured lipid carriers calculated using the following equation;

$$\text{DEE (\%)} = \frac{Total\ amount\ of\ drug\ recovered}{Total\ amount\ of\ drug\ added} \times 100$$

2.3.3 *In vitro* release studies

The dialysis technique was utilized for *in vitro* drug release from the NLCs **[16].** Dialysis bag of cellulose dialysis membrane (MW cut- off 10,000 Da) was soaked in the distilled water overnight and then 1ml of drug loaded NLCs formulation was taken in dialysis bag with both the ends sealed with threads. Initial

studies were carried out in 100 ml of 0.1N HCl (pH 1.2) for 2 hours and then in phosphate-buffered saline (PBS) pH 6.8 at 37°C on magnetic stirrer moving at a speed of 50 rpm for 24hrs[17]. The pH of formulation was adjusted with 2N HCl or 2N NaOH. Samples were taken out at predetermined time intervals and replaced with fresh media. Samples were filtered and analysed by using HPLC at λmax of 350 nm **[18].** All the values obtained were expressed as mean ± standard error mean (S.E.M.). Each data represents mean ± SD (n=3).

2.3.4 Scanning electron microscopy

Nifedipine loaded NLCs with tamarind polysaccharide was visualized by scanning electron microscopy for the surface morphology [**19].** Before observation, the NLCs were fixed on a double-sided sticky tape which had previously been secured on aluminum stubs and then coated with gold with thickness about 450 Å using Sputter gold coater and were visualized under scanning electron microscope.

III. Results And Discussion

Nifedipine loaded NLCs with coating of tamarind seeds polysaccharide were successfully formulated by solvent injection technique which depends upon high speed diffusion of the solvent over the solvent–lipid interfaced with the aqueous phase and this physical phenomenon is used to evaluate for the precipitation of nano sized lipid particle. The small size NLCs found may couple with low density of lipids. To control this limitation, the pH was decreased to 1.5–2 to maintain the zeta potential to a level that raise the aggregation of NLCs. The purity of the NLCs obtained is another significant characteristic in formulation of NLCs. A feasibility of free Nifedipine particles in the sediment of Nifedipine loaded NLCs with tamarind polysaccharide can't be refused. The *in vitro* and *in vivo* release behaviour of drug can affect the free drug particles. Therefore, dialysis technique was utilized to remove out the free drug particles from the sediment of NLCs formulation. Nifedipine have low molecular weight of 346.335 g/mol so that this method was considered appropriate to remove the free drug particles.

3.1 **Optimization of various parameters by Full Factorial Design**

The test factors for optimization of process parameters are summarized in **Table 2** and the results obtained after implementing 2^3 Full Factorial Design are summarized in **Table 3**.

Table 2: Test factors for optimization of process parameters for Nifedipine loaded NLCs with tamarind Seed Polysaccharide

Factor	**Name**	**Low level (-)**	**High level (+)**
A (X_1)	Amount of Oleic acid	10mg	20mg
B (X_2)	Amount of Glyceryl monosterate	100mg	200mg
C (X_3)	Amount of tamarind Seed Polysaccharide	40mg	50mg

Characterization of optimized nanostructured lipid carriers formulations

Table 3: Effect of Various Parameters on Characteristics of Tamarind seed polysaccharide coated NLCs

Batch Code	**A: Amount of GMS acid (mg)**	**B: Amount of oleic acid (lipid) (mg)**	**C: Amount of TSP (mg)**	**Y1: Particle size ±S.D**	**Y2: Entrapment Efficiency (%w/w)**
T_1	100 (-)	10 (-)	40(-)	259.5±**6.2**	69.16±**1.2**
T_2	200(+)	10 (-)	40(-)	257.1±**7.3**	79.12±**2.5**
T_3	100 (-)	20 (+)	40(-)	262.3±**3.5**	65.47±**7.2**
T_4	200 (+)	20(+)	40(-)	253.8±**7.3**	76.04±**3.5**
T_5	100 (-)	10(-)	50(+)	259.2±**1.2**	63.22±**2.9**
T_6	200(+)	10(-)	50(+)	261.3±**1.2**	82.56±**2.5**
T_7	**100(-)**	**20 (+)**	**50(+)**	**285.1±4.6**	**77.38±5.6**
T_8	200 (+)	20 (+)	50(+)	289.1±**6.2**	71.10±**4.2**

3.2 Calculation of Main and Interaction Effects

a) For Y_1: Particle sizes

The main and interaction effects of Tamarind seeds polysaccharide coated NLCs are summarized in **Table 4** and **Table 5**.

Table 4: Effect of Independent variables on Dependent variables

Batch Code	Main Effects			Interaction Effects				Response
	A	B	C	AB	AC	BC	ABC	Y_1
T_1	-	-	-	+	+	+	-	259.5±**6.2**
T_2	+	-	-	-	-	+	+	257.1±**7.3**
T_3	-	+	-	-	+	-	+	262.3±**3.5**
T_4	+	+	-	+	-	-	-	253.8±**7.3**
T_5	-	-	+	+	-	-	+	259.2±**1.2**
T_6	+	-	+	-	+	-	-	261.3±**1.2**
T_7	-	+	+	-	-	+	-	**285.1±4.6**
T_8	+	+	+	+	+	+	+	289.1±**6.2**
Effect	**-8.397**	**-1.017**	**-1.117**	**-6.252**	**+1.867**	**-2.367**	**-6.557**	**76.85**

Table 5: Summarized results of main and interaction effects (Y_1)

Coefficient	Effect
A	**-8.397**
B	**-1.017**
C	**-1.117**
AB	**-6.252**
AC	**+1.867**
BC	**-2.367**
ABC	**-6.557**

The regression equation obtained after calculation of main and interaction effect is represented in **Eq. 1** and the corresponding Pareto chart is shown in **Figure 1**.

Y_1=76.85250 -8.39750A -1.01750B–1.11750C–6.25250AB+1.86750AC -2.36750BC – 6.55750ABC (Eq. 1)



Figure 1

b) For Y_2: Entrapment Efficiency (%w/w)
The main and interaction effects are summarized in **Table 6** and **Table 7**.

Table 6: Effect of Independent variables on Dependent variables (Y_2)

Batch Code	Main Effects			Interaction Effects				Response
	A	B	C	AB	AC	BC	ABC	Y_2
N_1	-	-	-	+	+	+	-	69.16±**1.2**
N_2	+	-	-	-	-	+	+	79.12±**2.5**
N_3	-	+	-	-	+	-	+	65.47±**7.2**
N_4	+	+	-	+	-	-	-	76.04±**3.5**
N_5	-	-	+	+	-	-	+	63.22±**2.9**
N_6	+	-	+	-	+	-	-	82.56±**2.5**
N_7	-	+	+	-	-	+	-	**77.38±5.6**
N_8	+	+	+	+	+	+	+	71.10±**4.2**
Effect	**+1.200**	**-13.30**	**-15.50**	**-1.050**	**-4.250**	**-13.55**	**+2.000**	**272.35**

Table 7: Summarized results of main and interaction effects (Y_2)

Coefficient	Effect
A	+1.200
B	-13.30
C	-15.50
AB	-1.050
AC	-4.250
BC	-13.55
ABC	+2.000

The regression equation obtained after calculation of main and interaction effect is represented in **Eq. 2** and the corresponding Pareto chart is shown in **Figure 2**.

Y_2= 272.35000+1.20000A-13.30000B-15.50000C-1.05000AB+4.25000AC-13.55000BC+2.0ABC (Eq. 2)



Figure 2

3.3 **Particle Size Distribution of Optimized Batch**



Figure 3

3.4 *In vitro* drug release

The optimized batch was subjected to *in vitro* drug release studies for 2 hrs in 0.1N HCl and further upto 24 hrs in phosphate buffer (pH 6.8) by dialysis bag technique using dialysis membrane. In vitro release rate of Nifedipine loaded NLCs is graphically presented in Figure 4. As both particle size and entrapment efficiency are determinants of drug release from a given carrier system, the *in vitro* release profile were expected to vary accordingly. In 2hrs, 12hrs and 24hrs of the release study, the %CDR observed was 1.12±0.004%, 59.63±0.13% and 91.96±0.19 %. The formulation N_6 with particle size of 261.3±**1.2** nm and highest entrapment efficiency displayed maximum %CDR in a sustained manner.



Figure 4

3.5 **SEM image of optimized NLCs**



Figure5

IV. Conclusion

Using solvent injection technique, Nifedipine loaded NLCs coated with tamarind seed polysaccharide formulations which can be potentially useful for delivery of this drug. From *in vitro* drug release study, it was concluded that the NLCs with tamarind seed polysaccharide formulation delayed the drug release for two hours and controlled drug release upto 24 hrs. The result obtained from the study showed that the NLCs developed for oral delivery of Nifedipine possessed site specific targeting ability, better stability and higher entrapment efficiency, easy to scale up. The results of the present investigation showed that the problems associated with the oral bioavailability of Nifedipine could be overcome by incorporating it into a new gastrointestinal drug delivery system, nanostructured lipid carriers.

References

[1]. O'Driscoll, C.M., Griffin, B.T: Biopharmaceutical challenges associated with drugs with low aqueous solubility—the potential impact of lipid-based formulations. Adv. Drug Deliv. Rev. 2008; 60, 617–624.
[2]. Müller, R.H: Solid nanoparticle (SLN) and nanostructured lipid carrier (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 2002; 54, 131–155.
[3]. Ekambaram, P., Sathali, A.S., Priyanka, K: Solid lipid nanoparticles: A review. Sci Revs Chem Commun.2012; 2(1), 80- 102.
[4]. Sano M, Miyata E, Tamano S, Hagiwara A, Ito N, Shirai T: Lack of carcinogenicity of tamarind seed polysaccharide in B6C3F1 mice. Food Chem Toxicol.1996; 34,7-463.
[5]. Burgalassi S, Panichi L, Saettone MF, Jacobsen J, Rassing MR: Development and in vitro/in vivo testing of mucoadhesive buccal patches releasing benzydamine and lidocaine. Int J Pharm1996; 133, 1-7.
[6]. Sumathi S, Ray AR: Release behaviour of drugs from tamarind seed polysaccharide tablets. J Pharm Pharm Sci.2002; 5, 8-12.
[7]. Kulkarni D, Ddwivedi DK, Sarin JP, Singh S: Tamarind seed polyose: A potential polysaccharide for sustained release of verapamil hydrochloride as a model drug. Indian J Pharm Sci. 1997; 59:1-7.
[8]. Saettone MF, Burgalassi S, Giannaccini B, Boldrini E, Bianchini P, Luciani G: Ophthalmic solutions viscosified with tamarind seed polysaccharide. International Patent Application Number . PCT Int Appl WO.1997; 97 28,787.
[9]. Ghelardi E, Tavanti A, Celandroni F, Lupetti A, Blandizzi C, Boldrini E: Effect of a novel mucoadhesive polysaccharide obtained from tamarind seeds on the intraocular penetration of gentamicin and ofloxacin in rabbits. J Antimicrob Chemother.2000; 46,4-831.
[10]. Sahoo R, Sahoo S, Nayak PL: Release behavior of anticancer drug paclitaxel from tamarind seed polysaccharide galactoxyloglucan. Eur J Sci Res. 2010; 47,197-206.
[11]. Rao PS, Ghosh TP and Krishna S., 1946. Extraction and purification of Tamarind seed Polysaccharide. J Sci Ind Research (India), 4,705.
[12]. Pathak kamla, Tiwari Radheshyam: Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: Comparative analysis of characteristics, pharmacokinetics and tissue uptake, International Journal of Pharmaceutics 2011; 415, 232– 243.
[13]. Taoran Wang, Qiaobin Hu, Mingyong Zhou, Jingyi Xue, Yangchao Luo: Preparation of ultra-fine powders from polysaccharide-coated solid lipid nanoparticles and nanostructured lipid carriers by innovative nano spray drying technology International Journal of Pharmaceutics 2016; 511, 219–222.
[14]. Pathakkamla, TiwariRadheshyam: Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: Comparative analysis of characteristics, pharmacokinetics and tissue uptake, International Journal of Pharmaceutics 2011; 415, 232– 243.
[15]. Chun-Yang Zhuang, Ning Li, Mi Wang, Xiao-Ning Zhang, Wei-San Pan, Jun-Jai Peng, Yu-Sheng Pan, Xin Tang: Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability, International Journal of Pharmaceutics 2010; 394,179-185.
[16]. M.Y.Levy,S. Benita: Drug release from submicronized o/w emulsion: a new in vitro kinetic evaluation model, Int.J.Pharm1990; 66: 29-37.
[17]. Rania A. Sanad, NevineShawky, Abdel Malak, Tahany S. Bayoomy, Alia A. Badawi: Formulation of a Novel Oxybenzone-Loaded Nanostructured Lipid Carriers (NLCs). AAPS PharmSciTech. 2010; 11(4), 1684-1694.

[18]. Shailesh S.Chalikwar, veena S. Belgamwar, Vivek R. Talele, Sanjay J. Surana, Mrunal.Patil: Formulation and evaluation of nimodipine-loaded solid lipid nanoparticles delivered via lymphatic transport system. Colloids and Surfaces B: Biointerfaces. 2012; 97:109-116.
[19]. Varshosaz, J.,Minayian, M., Moazen, E: Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles. J. Liposome Res. 2010; 20: 115–123.
[20]. Ranjan Kumar Barman, Yasunori Iwao, Md. Rafiqul Islam, Yuka Funakoshi, Shuji Noguchi, Mir Imam Ibne Wahed, Shigeru Itai: In Vivo Pharmacokinetic and Hemocompatible Evaluation of Lyophilization Induced Nifedipine Solid-Lipid Nanoparticle Pharmacology & Pharmacy.2014; 5: 455-461.

Birendra Shrivastava, et. al. "Preparation and Development of Tamarind Seed Polysaccharide-Coated Nanostructured Lipid Carriers for Oral Delivery of Nifedipine." *IOSR Journal of Pharmacy and Biological Sciences (IOSR-JPBS)*, 16(2), (2021): pp. 01-08.